Pfizer: We hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026,…
Pfizer (PFIZER) filed a disclosure titled "We hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer…". The company is valued at about…
What happened
Pfizer (PFIZER) filed a disclosure with the exchanges on 29 September 2026 at 01:03 PM titled "We hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax Transfer…".
Company snapshot
Pfizer is a small-cap company in the Healthcare sector, with a market value of about ₹18,070 crore.
The stock last traded at ₹3,950, against a 52-week range of ₹3,955.5–₹5,578.5 (29.2% below the high).
Before this filing the shares had moved −15.6% over the month and −9.9% over three months. Average daily turnover over the last 20 sessions was about ₹21.41 crore.
Promoters held 63.92% at the end of Q1 FY27. Foreign institutions owned 1.65% and domestic institutions 17.80%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 603 | 191.8 | 41.91 |
| Q2 FY26 | 1,245 | 380.8 | 83.23 |
| Q3 FY26 | 645 | 141.8 | 31.01 |
| Q4 FY26 | 629 | 199.8 | 43.68 |
| Q1 FY27 | 653 | 204.5 | 44.69 |
What history shows
BCEIE has no earlier regulatory filing from this company on record since May 2026.
Across 153 similar disclosures by other Healthcare companies, shares moved +0.3% on average the next day and +1.3% over five days; 48% of them rose the next day.
Market-wide, 5,432 regulatory filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
- Pfizer India removes products from Karnataka markets after spurious drugs crackdown
- Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices
- Patient safety top priority, working with authorities on counterfeit medicine probe: Pfizer India
- Novartis India buys Pfizer's Minipress (prazosin) brands for USD 150M
- Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.